Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.
The company’s vision is to contribute to better and cheaper medicine through porous silica. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the production costs at the manufacturers. In Drug Development, the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.
Forskargatan 20 G, 15136 Södertälje – Sweden
|Date||Trading entity / Person||Association||Trade type||Volume|
|10.10.22||Tomas Kramar||Other||Buy||SEK 166,000.00|
|10.10.22||Tomas Kramar||Other||Buy||SEK 100,000.00|
|05.10.22||Sitbon Bioscience Partner ZENZ AB||Other||Buy||SEK 66,660.00|
|08.06.21||Andreas Bhagwani||Other||Buy||SEK 1,348,500.00|
|08.06.21||Andreas Bhagwani||Other||Sell||SEK 1,020,000.00|
|08.06.21||Andreas Bhagwani||Other||Other||SEK 767,863.80|
|08.06.21||Andreas Bhagwani||Other||Buy||SEK 503,652.60|
|08.06.21||Tomas Kramar||Other||Buy||SEK 300,000.00|
|08.06.21||Investmentaktiebolaget Akkumula||Other||Buy||SEK 150,000.00|
|07.06.21||Mattias Bengtsson||Other||Buy||SEK 195,000.00|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.